First-time Usage of SGLT2 Inhibitors in Type 2 Diabetic Patients Who Are Fasting During Ramadan: Safety and Efficacy
Conditions: SGLT2 Inhibitors, First Time Use; Type2 Diabetes; Fasting in Ramadan Interventions: Diagnostic Test: HbA1c, serum creatinine, eGFR urine analysis and serum electrolyte Na and K Sponsors: Sohag University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
Conditions: Non-Alcoholic Fatty Liver Disease Interventions: Drug: Empagliflozin 10 MG; Drug: Placebo Oral Tablet Sponsors: Ann& Robert H Lurie Children ' s Hospital of Chicago Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction
Conditions: Heart Failure, Preserved Ejection Fraction Interventions: Drug: SGLT2 inhibitor Sponsors: Samsung Medical Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
SGLT2 Inhibitors and Perioperative Period
Conditions: Perioperative Complication Interventions: Drug: SGLT2 inhibitor Sponsors: Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 22, 2024 Category: Research Source Type: clinical trials
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Conditions: Type 2 Diabetes Interventions: Drug: Retatrutide; Drug: Placebo Sponsors: Eli Lilly and Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 7, 2024 Category: Research Source Type: clinical trials
Renal Mechanism of SGLT2 Inhibition
Conditions: Type 2 Diabetes; Diabetic Kidney Disease Interventions: Drug: SGLT2 inhibitor Sponsors: University of Michigan; University of Colorado, Denver; Renal Pre-Competitive Consortium (RPC3) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 4, 2024 Category: Research Source Type: clinical trials
Effect sglt2 inhibitors on contrast medium induced acute kidney injury
Conditions: Chronic Kidney Diseases; Type2diabetes Sponsors: University of Health Sciences Balikesir Hospital Eduation and Research Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 1, 2024 Category: Research Source Type: clinical trials
Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels
Conditions: Hematocrit Change; Cardiovascular Prevention; Empagliflozin; SGLT2-Inhibitors; Tissue Oxygenation Interventions: Drug: Empagliflozin10Mg Tab Sponsors: Aristotle University Of Thessaloniki Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
Using of SGLt2 Inhibitors in Patients With Type 2 DM
Conditions: Type 2 Diabetes Interventions: Drug: SGLT2 inhibitor Sponsors: Assiut University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 21, 2024 Category: Research Source Type: clinical trials
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Conditions: Diabetes Mellitus, Type 2 Interventions: Drug: Retatrutide; Drug: Semaglutide Sponsors: Eli Lilly and Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 15, 2024 Category: Research Source Type: clinical trials
Impact of Sodium-glucose Cotransporter 2 Inhibitors on Post-operative Atrial Fibrillation in Cardiothoracic Surgery
Conditions: Atrial Fibrillation Interventions: Drug: SGLT2 inhibitor Sponsors: Hamad Medical Corporation Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials
Role of SGLT2I in Patients With Myocardial Infarction
Conditions: Myocardial Infarction; Diabetes Mellitus Interventions: Drug: SGLT2 inhibitor Sponsors: Dongying Zhang Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
Ketones, SGLT2, HFrEF
Conditions: Type2diabetes; Heart Failure With Reduced Ejection Fraction Interventions: Drug: Empagliflozin 25 MG Oral Tablet; Drug: Placebo; Drug: Acipimox 250 Mg Oral Capsule Sponsors: The University of Texas Health Science Center at San Antonio; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 29, 2024 Category: Research Source Type: clinical trials
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Conditions: Type 2 Diabetes Interventions: Drug: Cagrilintide; Drug: Semaglutide; Drug: Tirzepatide Sponsors: Novo Nordisk A/S Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 24, 2024 Category: Research Source Type: clinical trials
Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients
Conditions: Genetic Polymorphisms; Heart Failure Interventions: Drug: SGLT2 inhibitors (Dapagliflozin and Empagliflozin) Sponsors: October 6 University; University of Florida; National Heart Institute, Egypt; Beni-Suef University Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 11, 2024 Category: Research Source Type: clinical trials
